Report Published: "Egypt Pharmaceuticals & Healthcare Report Q3 2016"

Underlying issues relating to intellectual property and medicine pricing highlight the challenging nature of Egypt's pharmaceutical market for innovative drugmakers looking to establish a presence in this North African country. Despite this, Egypt continues to attract a significant deal of attention from multinational drugmakers, albeit largely through imports and/or contract manufacturing agreements. Over the long-term, we view Egypt's pharmaceutical and healthcare sectors as having enormous growth potential, supported by a promising manufacturing base and the government's continual commitment to advancing healthcare on a national-scale. Economic and political volatilities will remain influential factors determining company interest.Headline Expenditure ProjectionsPharmaceuticals: EGP33.08bn (USD4.29bn) in 2015 to EGP36.82bn (USD4.23bn) in 2016; +11.3% in local currency terms and -1.5% in US dollar terms. Forecast unchanged from Q 2 1 6 .

Full Report Details at
- http://www.fastmr.com/prod/1172834_egypt_pharmaceuticals.aspx?afid=301

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016
- China Pharmaceuticals & Healthcare Report Q3 2016
- Italy Pharmaceuticals & Healthcare Report Q3 2016